DA-7503 / Dong-A - LARVOL DELTA

Therapeutic Evaluation Of DA-7503, A Tau Aggregation Inhibitor, Alone And In Combination With Lecanemab In Tauopathy & AD Models (AAIC 2026) - No abstract available

Combination therapy

Dong-A ST reports preclinical gains for two Alzheimer's drugs, eyes Korea trials (Chosun Biz) - "At the conference, Dong-A ST unveiled preclinical results on the GPX4 activator 'DA-7505' and the tau aggregation inhibitor 'DA-7503' through a poster presentation...In this study, cognitive function improved in an Alzheimer's mouse model, and superior anti-inflammatory effects were confirmed compared with conventional reactive oxygen species (ROS) scavenging approaches...The second candidate, DA-7503, is a new drug that inhibits the aggregation of tau protein, cited as another key cause of Alzheimer's disease...In preclinical studies, even low doses improved cognitive and motor functions in a tauopathy mouse model, with greater efficacy at higher doses. It also reduced hyperphosphorylation, aggregation, and accumulation of tau in the brain, improving overall tau pathology."

Preclinical • Alzheimer's Disease

A Study to Evaluate Safety, Tolerability, and PK of DA-7503 in Healthy Adult and Elderly Participants (clinicaltrials.gov) - P1 | N=90 | Completed | Sponsor: Dong-A ST Co., Ltd. | Not yet recruiting ➔ Completed | Trial completion date: May 2025 ➔ Jan 2026 | Trial primary completion date: May 2025 ➔ Jan 2026

Trial completion • Trial completion date • Trial primary completion date

Drug Development. (PubMed, Alzheimers Dement) - "Our findings suggest that DA-7503, a novel tau aggregation inhibitor with great potencies against pathological 3R and 4R tau isoforms and a favorable non-clinical safety profile, effectively restored motor function and reduced tau aggregates in the JNPL3 mouse model of tauopathy. These results highlight DA-7503's potential as a promising therapeutic candidate for Alzheimer's disease and primary tauopathies, including frontotemporal dementia, progressive supranuclear palsy and corticobasal degeneration. DA-7503 is currently undergoing a phase 1 clinical study."

Journal • Alzheimer's Disease • CNS Disorders • Dementia • Frontotemporal Lobar Degeneration • Movement Disorders • Progressive Supranuclear Palsy

K Pharmaceutical Bio, Alzheimer's disease largest conference 'AAIC' sortie... Aiming for 'Tau·BBB·AI diagnosis' [Google translation] (BioNews) - "Dong-A ST will present a poster for 'DA-7503 (development code name)' for the second consecutive year. DA-7503 is a small molecule tau aggregation inhibitor currently under development as a treatment for Alzheimer's disease and tauopathy. DA-7503 selectively acts on separated and modified tau, inhibiting oligomer formation and thereby inhibiting intracellular tau accumulation. Following last year, preclinical data on DA-7503 related to Alzheimer's disease and tauopathy will be released this year as well."

Preclinical • Alzheimer's Disease • Tauopathies And Synucleinopathies

Drug Development. (PubMed, Alzheimers Dement) - "DA-7503 restores the impairments of memory and recognition, and ameliorates the aggregation and hyperphosphorylation of tau in transgenic mouse models of AD and other tauopathies. The inverse correlation between total Tau in CSF and DA-7503 exposure in plasma suggests that DA-7503 induces an increase of tau clearance from the brain and CSF tau may be explored as a biomarker in clinical development of DA-7503. Our findings indicate DA-7503 is a promising agent for the treatment of AD and primary tauopathies."

Journal • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • CSF T-tau

DA-7503, a novel tau aggregation inhibitor, ameliorates tau pathology and reduces CSF tau in transgenic mouse models of Alzheimer’s disease and primary tauopathies (AAIC 2024) - "DA-7503 restores the impairments of memory and recognition, and ameliorates the aggregation and hyperphosphorylation of tau in transgenic mouse models of AD and other tauopathies. The inverse correlation between total Tau in CSF and DA-7503 exposure in plasma suggests that DA-7503 induces an increase of tau clearance from the brain and CSF tau may be explored as a biomarker in clinical development of DA-7503. Our findings indicate DA-7503 is a promising agent for the treatment of AD and primary tauopathies."

Preclinical • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • CSF T-tau

A Study to Evaluate Safety, Tolerability, and PK of DA-7503 in Healthy Adult and Elderly Participants (clinicaltrials.gov) - P1 | N=72 | Not yet recruiting | Sponsor: Dong-A ST Co., Ltd.

New P1 trial